Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H20O2 |
Molecular Weight | 184.2753 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCCCCCCC=C
InChI
InChIKey=FRPZMMHWLSIFAZ-UHFFFAOYSA-N
InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2H,1,3-10H2,(H,12,13)
Molecular Formula | C11H20O2 |
Molecular Weight | 184.2753 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.fda.gov/ohrms/dockets/ac/04/briefing/4036B1_06_OTC%20Monograph%20Topical.htmCurator's Comment: description was created based on several sources, including
http://www.altmedrev.com/publications/7/1/68.pdf |
https://www.ncbi.nlm.nih.gov/pubmed/10991877
Sources: https://www.fda.gov/ohrms/dockets/ac/04/briefing/4036B1_06_OTC%20Monograph%20Topical.htm
Curator's Comment: description was created based on several sources, including
http://www.altmedrev.com/publications/7/1/68.pdf |
https://www.ncbi.nlm.nih.gov/pubmed/10991877
Undecylenic acid is unsaturated fatty acid, which naturally occurs in sweat, and is commercially produced by the vacuum distillation of castor bean oil. It is recognized as GRASE by FDA, and is marketed over the counter to treat skin infections and to relieve itching. Undecylenic acid acts by inhibition of morphogenesis from yeast to hyphae forms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10991877 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CRUEX Approved UseFor the cure of most tinea pedis (athlete's foot) and tinea corporis (ringworm). |
|||
Curative | CRUEX Approved UseFor the cure of most tinea pedis (athlete's foot) and tinea corporis (ringworm). |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | CRUEX Approved UseItching, burning, redness, irritation, scaling, soreness and discomfort which may accompany these conditions |
Doses
Dose | Population | Adverse events |
---|---|---|
2.2 g 3 times / day multiple, oral Dose: 2.2 g, 3 times / day Route: oral Route: multiple Dose: 2.2 g, 3 times / day Co-administed with:: nicotinic acid(50 mgm. morning and night) Sources: |
unhealthy, 56 years n = 1 Health Status: unhealthy Condition: psoriasis Age Group: 56 years Sex: M Population Size: 1 Sources: |
Disc. AE: Toxic labyrinthitis... AEs leading to discontinuation/dose reduction: Toxic labyrinthitis (1 patient) Sources: |
1 g 3 times / day multiple, oral Dose: 1 g, 3 times / day Route: oral Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, 8-14 years n = 4 Health Status: unhealthy Condition: psoriasis | NEURODERMATITIS Age Group: 8-14 years Population Size: 4 Sources: |
|
10 g 3 times / day multiple, oral Highest studied dose Dose: 10 g, 3 times / day Route: oral Route: multiple Dose: 10 g, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: psoriasis Age Group: adult Sources: |
|
2 % 1 times / day multiple, topical Dose: 2 %, 1 times / day Route: topical Route: multiple Dose: 2 %, 1 times / day Co-administed with:: zinc undecylenate(0.2) Sources: |
unhealthy n = 29 Health Status: unhealthy Condition: TINEA PEDIS Population Size: 29 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Toxic labyrinthitis | 1 patient Disc. AE |
2.2 g 3 times / day multiple, oral Dose: 2.2 g, 3 times / day Route: oral Route: multiple Dose: 2.2 g, 3 times / day Co-administed with:: nicotinic acid(50 mgm. morning and night) Sources: |
unhealthy, 56 years n = 1 Health Status: unhealthy Condition: psoriasis Age Group: 56 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
Mutations in erg4 affect the sensitivity of Saccharomyces cerevisiae to medium-chain fatty acids. | 2002 Apr 15 |
|
Self-assembled thermo- and pH responsive micelles of poly(10-undecenoic acid-b-N-isopropylacrylamide) for drug delivery. | 2006 Dec 1 |
|
Natural treatment of chronic rhinosinusitis. | 2006 Sep |
|
Grazing angle mirror-backed reflection (GMBR) for infrared analysis of monolayers on silicon. | 2006 Sep 14 |
|
Structure and polymer form of poly-3-hydroxyalkanoates produced by Pseudomonas oleovorans grown with mixture of sodium octanoate/undecylenic acid and sodium octanoate/5-phenylvaleric acid. | 2007 Jan 30 |
|
Topographical and functional characterization of the ssDNA probe layer generated through EDC-mediated covalent attachment to nanocrystalline diamond using fluorescence microscopy. | 2008 Aug 19 |
|
Simultaneous biosynthesis of two copolymers in Pseudomonas putida GPo1 using a two-stage continuous culture system. | 2010 Jun 14 |
Patents
Sample Use Guides
Undecylenic acid antifungal liquid should be applied to affected area topically.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10991877
To investigate effect of undecylenic acid on Candida albicans morphogenesis, cells were grown overnight at 30°C on YPD agar and harvested by scraping the cells from the plate and suspending in YPD broth. Two milliliters of cells at 106 cells/ml was distributed into tubes containing liner, approximately 0.5 g of liner per tube. The cultures were incubated at 39°C with agitation for 2 h; planktonic cells were analyzed microscopically to determine the percentage of cells with germ tubes. The presence of Undecylenic acid inhibited the appearance of germ tubes, with 10 μM UDA causing a sevenfold reduction.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:09:42 GMT 2023
by
admin
on
Fri Dec 15 15:09:42 GMT 2023
|
Record UNII |
K3D86KJ24N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2995 (Number of products:4)
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
WHO-VATC |
QD01AE54
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
DSLD |
3453 (Number of products:1)
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
WHO-VATC |
QD01AE04
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
JECFA EVALUATION |
10-UNDECENOIC ACID
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
WHO-ATC |
D01AE04
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
CFR |
21 CFR 333.210
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
WHO-ATC |
D01AE54
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
EPA PESTICIDE CODE |
85501
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8035001
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
112-38-9
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
UNDECYLENIC ACID
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
1705505
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
203-965-8
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
39448
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
100000091959
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
K3D86KJ24N
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
K3D86KJ24N
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
3446
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
35045
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
10989
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
SUB15654MIG
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
C538763
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
314881
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
ALTERNATIVE | |||
|
C29530
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
m11303
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
373
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL1276010
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
2013
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
DB11117
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY | |||
|
5634
Created by
admin on Fri Dec 15 15:09:42 GMT 2023 , Edited by admin on Fri Dec 15 15:09:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |